All Episodes

FCR vs. BR - Is One Better?

Basics of Small Cell Lung Cancer

Adjuvant Chemotherapy for Elderly and Frail Patients

Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1

New Trials of Targeting Therapies to Treat Leptomeningeal Carcinomatosis

ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments

Immuno-oncology Developments - Combinations and Use as First-Line Therapy

Does Current Evidence Support Favoring Proton-Beam Radiation

J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?

Are There Less Toxic Alternatives to the Extreme Regimen

Promising Early Data for Oral Inhibitor Buparlisib

Using Immunotherapy as First-Line Treatment and in Combinations

Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients

Using Biomarkers in Immunotherapy

Common Side Effects of PD-1 Inhibitors

Data from Keynote 12 Nivolumab and Pembrolizumab

How Promising Are The Results From Checkmate 141?

Local Consolidation Therapies for Oligomatastases

The Immune System and PD-1 Inhibitors

Urine or Blood Testing Instead of Lung Biopsy Shows Promise for Finding EGFR Mutations

Can Online Patient Groups Speed New Targeted Therapies?

Rova-T Shows Promise in Small Cell Lung Cancer

Significance Of IGHV Mutations & How They Are Assessed

Immunotherapy Combinations

Immunotherapy as First-Line Treatment

Lung Cancer Screening - Process and Potential Benefits

Bronchoscopy and EBUS

Maintenance Therapy for Advanced NSCLC

Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

Histology-Specific Recommendations - Large-Cell Neuroendocrine

Histology-Specific Regimens - Squamous

Histology-Specific Regimens - Adenocarcinoma

What is the Role of Bevacizumab in Stage IV NSCLC?

Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment

Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

ROS-1 Rearrangements: What Are They?

ALK Rearrangements: What Are They, and Who Has Them?

Multiplex Testing for Rare Mutations: What Are the Potential Benefits?

The Role of Targeted Therapy Post-Resection

What Is a Standard Adjuvant Chemotherapy Regimen?

Why Give Adjuvant Chemotherapy, and to Which Patients?

Zoledronate or Denosumab for Lung Cancer with Bone Metastases

How Rate of Progression Can Affect Treatment Decisions

Platinum-Based Doublets As the Cornerstone of First Line Treatment

What are the Goals of Treating Advanced NSCLC?

Video-Assisted Thorascopic Surgery vs. Open Thoracotomy

What Is the Significance of Mediastinal Node Sterilization After Neoadjuvant Therapy?

What Is a Sleeve Resection?

What Is a Mediastinoscopy?

How Do Thoracic Surgeons Assess Fitness for Surgery?

The Surgical Decision: Assessing and Discussing the Patient's Options

Is There a Role for PCI in Locally Advanced NSCLC?

Can Immunotherapy Play a Role in Locally Advanced NSCLC?

Appropriate Chemo Regimens with Radiation for Locally Advanced NSCLC

Is Targeted Therapy Feasible As Consolidation in Locally Advanced NSCLC?

Is There a Role for Induction or Consolidation Chemotherapy Before/After Chemo/Radiation?

Chemoradiation as a Standard of Care for Unresectable NSCLC

What is Stage III Unresectable NSCLC?

Trends in Lung Cancer Demographics and Changes in Histology

Lung Cancer Risk Factors

Lung Cancer Demographics/Epidemiology

Are There Significant Genetic Risks for Lung Cancer?

Local Therapy for Limited Acquired Resistance

Elderly Patients: Selecting Appropriate Systemic Treatment Agents

Elderly Patients: Single Agent vs. Doublet Chemotherapy

The Basics of a Lung Cancer Workup

What Are Pulmonary Function Tests, and How Are They Used?

PET Scan Imaging: What Does It Tell Us?

How a Diagnosis of Lung Cancer is Made: The Biopsy

Potential Advantages, Disadvantages and Limitations of Lung Cancer Screening

Detecting Lung Cancer: Presenting Symptoms

Predictive Testing for Chemotherapy Responsiveness

HER2 Mutation Positive NSCLC

ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

Third Generation EGFR TKIs for Acquired Resistance

Targeted Therapies in a Post-Operative/Adjuvant Setting

Induction Chemotherapy Followed by Chemo/Radiation for Stage III NSCLC

Management of Locally Advanced NSCLC in the Elderly and Frail

Defining Resectability in Stage IIIA Lung Cancer

Neoadjuvant Chemotherapy vs. Chemo/Radiation for Stage IIIA NSCLC

Overall Management for Stage IIIA Disease

Managing Three Compartments in Stage III Disease (Local, Distant, CNS)

Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC

What is V20 and Why Do Radiation Dose & Field Size Matter?

High vs. Standard Dose Chest Radiation in Stage III Lung Cancer

SBRT for Oligometastatic Lung Cancer

SBRT for Medically Inoperable Stage I Lung Cancer

What is Stereotactic Radiosurgery/Radiation Therapy to the Brain or Body?

What is the Role of Molecular Marker Testing in the Adjuvant or Post-Op Setting?

SBRT as a Potential Alternative for Fit Patients with Early Stage Lung Cancer

Can Serum Tumor Markers Be Used in the Management of Lung Cancer?

Different Lung Cancer Subtypes - Histology

Immunotherapy for Small Cell Lung Cancer

Second Line Chemotherapy Options for SCLC

New Approaches to Immunotherapy